The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus

Robinson, George; Wilkinson, Meredyth G Ll; Wincup, Chris

doi:10.3389/fimmu.2021.806560

Cited by 14 publications

(13 citation statements)

References 94 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSPCs of SLE patients with severe diseases also had changes toward myelopoiesis, confirming the data from the mouse model (92). Metabolic changes impacting DNA methylation/demethylation have been reported in lupus patients (93) and mTOR implications are also reported to be involved in SLE patients (94,95). Inhibitors of mTOR like sirolimus and everolimus have proven effective in the treatment of lupus (96,97).…”

Section: Systemic Lupus Erythematosussupporting

confidence: 67%

Trained immunity as a possible newcomer in autoinflammatory and autoimmune diseases pathophysiology

Beignon

Galeotti²,

Schvartz³

2023

Front. Med.

View full text Add to dashboard Cite

Autoimmune disorders have been well characterized over the years and many pathways—but not all of them–have been found to explain their pathophysiology. Autoinflammatory disorders, on the other hand, are still hiding most of their molecular and cellular mechanisms. During the past few years, a newcomer has challenged the idea that only adaptive immunity could display memory response. Trained immunity is defined by innate immune responses that are faster and stronger to a second stimulus than to the first one, being the same or not. In response to the trained immunity inducer, and through metabolic and epigenetic changes of hematopoietic stem and progenitor cells in the bone marrow that are transmitted to their cellular progeny (peripheral trained immunity), or directly of tissue-resident cells (local innate immunity), innate cells responsiveness and functions upon stimulation are improved in the long-term. Innate immunity can be beneficial, but it could also be detrimental when maladaptive. Here, we discuss how trained immunity could contribute to the physiopathology of autoimmune and autoinflammatory diseases.

show abstract

Section: Systemic Lupus Erythematosussupporting

confidence: 67%

Trained immunity as a possible newcomer in autoinflammatory and autoimmune diseases pathophysiology

Beignon

Galeotti²,

Schvartz³

2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Systemic lupus erythematosus (SLE) is an autoimmune-mediated systemic inflammatory disease ( 116 ). Lupus nephritis (LN) is one of the most common complications of SLE and a major predictor of poor prognosis ( 117 ).…”

Section: Iguratimod In the Treatment Of Rheumatic Bone Diseases And A...mentioning

confidence: 99%

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Long,

Zeng,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Autoimmune diseases are affected by complex pathophysiology involving multiple cell types, cytokines, antibodies and mimicking factors. Different drugs are used to improve these autoimmune responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibodies, and small molecule drugs (DMARDs), which are prevalent clinically in the treatment of rheumatoid arthritis (RA), etc. However, low cost-effectiveness, reduced efficacy, adverse effects, and patient non-response are unattractive factors driving the development of new drugs such as iguratimod. As a new disease-modifying antirheumatic drug, iguratimod has pharmacological activities such as regulating autoimmune disorders, inflammatory cytokines, regulating immune cell activation, differentiation and proliferation, improving bone metabolism, and inhibiting fibrosis. In recent years, clinical studies have found that iguratimod is effective in the treatment of RA, SLE, IGG4-RD, Sjogren ‘s syndrome, ankylosing spondylitis, interstitial lung disease, and other autoimmune diseases and rheumatic diseases. The amount of basic and clinical research on other autoimmune diseases is also increasing. Therefore, this review systematically reviews the latest relevant literature in recent years, reviews the research results in recent years, and summarizes the research progress of iguratimod in the treatment of related diseases. This review highlights the role of iguratimod in the protection of autoimmune and rheumatic bone and related immune diseases. It is believed that iguratimod’s unique mode of action and its favorable patient response compared to other DMARDs make it a suitable antirheumatic and bone protective agent in the future.

show abstract

“…Systemic lupus erythematosus (SLE) is a multisystem inflammatory autoimmune disease, which is usually affects young and middle-aged women, characterized by production of autoantibodies and autoimmune inflammation. There are multiple factors involved in SLE pathogenesis and development, such as genetics, infection, hormone disorder and immune anomalies [ 1 , 2 ]. Among these factors, immune dysfunction has been found to be the critical driving factor for SLE, which characterized by loss of immune tolerance and overactive immune response.…”

Section: Introductionmentioning

confidence: 99%

The roles of adenosine signaling in systemic lupus erythematosus

Dong,

Wu,

Liu

et al. 2024

Heliyon

View full text Add to dashboard Cite

The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus

Cited by 14 publications

References 94 publications

Trained immunity as a possible newcomer in autoinflammatory and autoimmune diseases pathophysiology

Trained immunity as a possible newcomer in autoinflammatory and autoimmune diseases pathophysiology

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

The roles of adenosine signaling in systemic lupus erythematosus

Contact Info

Product

Resources

About